Tamibarotene
Tamibarotene is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against retinoic acid receptor alpha. In addition, it is known to target retinoic acid receptor gamma and retinoic acid receptor beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | 1 | — | — | 2 |
| Preleukemia | D011289 | — | — | — | 1 | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 2 |
| Bone marrow diseases | D001855 | — | — | — | 1 | 1 | — | — | 1 |
| Muscle spasticity | D009128 | HP_0001257 | — | — | 1 | 1 | — | — | 1 |
| Spinal cord diseases | D013118 | HP_0002196 | G95.9 | — | 1 | 1 | — | — | 1 |
| Tropical spastic paraparesis | D015493 | EFO_0007527 | G04.1 | — | 1 | 1 | — | — | 1 |
| Paraparesis | D020335 | HP_0002385 | G82.2 | — | 1 | 1 | — | — | 1 |
| Spastic paraparesis | D020336 | HP_0002313 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 2 | 3 | — | — | — | 4 |
| Promyelocytic leukemia acute | D015473 | — | C92.4 | 1 | 1 | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
| Pleural effusion | D010996 | HP_0002202 | J90 | — | 1 | — | — | — | 1 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 1 | — | — | — | 1 |
| Nephritis | D009393 | — | N05 | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tamibarotene |
| INN | tamibarotene |
| Description | Tamibarotene is a dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine. It has a role as an antineoplastic agent and a retinoic acid receptor alpha/beta agonist. It is a member of tetralins, a retinoid and a dicarboxylic acid monoamide. It is functionally related to a 4-carbamoylbenzoic acid and a terephthalic acid. |
| Classification | Small molecule |
| Drug class | arotinoid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21 |
Identifiers
| PDB | — |
| CAS-ID | 94497-51-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL25202 |
| ChEBI ID | 32181 |
| PubChem CID | 108143 |
| DrugBank | DB04942 |
| UNII ID | 08V52GZ3H9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
RARB
RARB
Organism
Homo sapiens
Gene name
RARB
Gene synonyms
HAP, NR1B2
NCBI Gene ID
Protein name
retinoic acid receptor beta
Protein synonyms
HBV-activated protein, hepatitis B virus activated protein, Nuclear receptor subfamily 1 group B member 2, RAR-beta, RAR-epsilon, retinoic acid receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Rarb (218772)
retinoic acid receptor beta (P22605)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 987 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use